Amy Cramer draws on her experience as a cardiac critical care nurse, clinical research coordinator, certified healthcare quality professional and clinical research informaticist. Ms Cramer has worked in a community hospital, an independent academic medical center, and world class academic medical institution. She is currently Johnson & Johnson Innovative Medicine Clinical Innovation Focus Area Leader: Capitalizing on Data Assets. She has been the Director of eSource Implementation for Pfizer, Inc. Ms Cramer’s focus throughout her career has been determining improvements that provide better patient centric care, whether that be developing a visualization for a complex hypoglycemia protocol, developing a transplant quality program or optimizing the use of the electronic health record for clinical research. Ms Cramer’s current focus is on clinical trials solutions, which includes eSource; specifically the secondary use of EHR data for clinical research. Ms Cramer is Co-Chair of HL7 Clinical Interoperability Council, AMIA’s Scientific Panel Committee, a TransCelerate member and reviewer for many professional journals. Ms Cramer received a Master in Management of Clinical Informatics from Duke University School of Medicine and plans to continue her studies in Clinical Research Informatics at the University of Arkansas for Medical Sciences.

Xiaoying Wu, MD, MS, is Vice President, Data Science Platforms and Privacy at Janssen and has more than 20 years of diverse experiences in medical sciences, data science, medical informatics, and information technology. Ms Wu’s recent accomplishments include establishing Janssen R&D Data Science ecosystem, Med.ai, that integrates diverse data from preclinical, clinical and real world; delivering innovative data science solutions to accelerate drug research and development at scale. Previously, Ms Wu led the Data Sciences Pharma Commercial Technology team, established an enterprise Real World Data and Analytical platform, rHEALTH, enabled JnJ as strategic leader demonstrating Real World value for Janssen products. In addition, she led the team delivering innovative solutions supporting GCSO and Janssen Commercial organization, including early disease identification, predictive HCP targeting, augment payer/provider strategy, as well as patient data anonymization and re-identification risk assessment. Ms Wu played a crucial role in molecular profiling, advanced analytics/visualization supporting TAs, including identification of prediction markers for patient stratification, developing and implementing computational framework for identify PD markers and genomic signatures for understanding molecular basis of disease and drug MOA as well as establishing a strategic technological foundation for Real World Data providing transparency and governance, advanced analytics capabilities and services to enable innovation, efficiencies, and rapid data-driven decision-making. Ms Yu is the author of over 30 peer-reviewed scientific publications. She received her MD from XiangYa School of Medicine, MS degrees in Computer Sciences and Biostatistics from Drexel University and University of Pennsylvania respectively.

Paul Bleicher, MD, PhD, is a consultant and advisor to healthcare and life science businesses, internationally. Dr Bleicher works with private equity investments in healthcare and life science IT/data as an executive partner at Ardan Equity and with pre-seed startup companies through his work as a founding apillar at Petri and PIllar.

Prior to these roles, Dr Bleicher was the chief executive officer of OptumLabs, an open, collaborative research and innovation center founded by Optum and Mayo Clinic to accelerate improvements in patient care and value through clinical, policy and product innovation driven by new insights from big data.

Before OptumLabs, Dr Bleicher was chief medical officer and a member of the Board of Directors of Humedica, a next-generation clinical informatics company that was acquired by Optum in January 2013. Before Humedica, Dr Bleicher was a founder and original CEO of Phase Forward, a company which pioneered the development of web-based electronic data capture for clinical trials and was acquired by Oracle Corporation in 2010. Dr Bleicher had previously led clinical development at a biotechnology company (Alpha-Beta Technology), and began his career in industry at PAREXEL, where he assisted pharmaceutical and biotechnology companies with the clinical development of novel therapies.

Dr Bleicher earned his BS from Rensselaer Polytechnic Institute and an MD/PhD from the University of Rochester School of Medicine and Dentistry. Dr Bleicher trained in internal medicine at the Beth Israel Hospital, in dermatology at Harvard Medical School/Massachusetts General Hospital, and was a post-doctoral fellow at the Dana Farber Cancer Institute in molecular biology before beginning his career as an assistant professor at the Massachusetts General Hospital and Harvard Medical School. Dr Bleicher has held various leadership positions and has received numerous awards for entrepreneurship and leadership in the pharmaceutical and healthcare industries.

Lekan Wang is Head of Machine Learning Services at Parexel. As a software and data executive with proven track record designing, building, and maintaining operational software products across the healthcare ecosystem, Mr Wang has architected and built data solutions used at numerous pharmaceutical and biotech firms, as well as provider systems, the NIH, NHS, FDA, and the CDC. He is an expert in deploying real-world integrated software platforms in challenging, complex environments that enable expert users while building in appropriate innovative technologies. As a previously founding member and lead at Palantir Technologies, Mr Wang initiated and led biopharma and US federal healthcare projects and helped seed London and Munich offices to serve EU pharma clients.

Victoria L. Chiou, MD, is Head, Clinical Excellence and Innovation, Late Development Oncology at AstraZeneca, where she leads strategic development and implementation of global initiatives at the intersection of clinical cancer research, technology, and innovation. Dr Chiou is an oncology research physician with academic, industry, and regulatory experience in patient-centric drug development. Prior diverse clinical development experiences include GlaxoSmithKline in cell therapy, and MedImmune/AstraZeneca in novel immuno-oncology drug combinations for treatment of multiple cancers. Dr Chiou also served as a medical officer at the US Food and Drug Administration, Office of Hematology and Oncology products.

Dr Chiou completed her BA in human biology and psychology as a Jefferson Scholar at University of Virginia, MD at Medical College of Virginia, internal medicine residency at Wake Forest University, and medical oncology fellowship at National Institutes of Health, National Cancer Institute. Multiple career recognitions include Conquer Cancer Foundation of ASCO Merit Award, ASCO/AACR Methods in Clinical Cancer Research Workshop, and SITC Women in Cancer Immunotherapy Network Leadership Institute.

Sheryl has more than 30 years of experience in both Pharma and Biotech industries, including executive leadership roles at Amgen, Pfizer, Pharmacia and Searle.  Most recently, she was the Vice President of Global Development Operations at Amgen leading a team of approximately 6200 staff across all Therapeutic Areas and all phases of Development.

Under Sheryl's leadership, the team doubled in size and expanded into new geographies in the Middle East and Asia.   She has deep data management experience and has been implementing AI / ML approaches to the operational delivery of clinical trials.  She also has significant experience representing the R&D function in due diligence activities and serving as the integration leader for Development since 2012.

Sheryl has significant experience in outsourcing models including Functional Service Provider and Full Service outsourcing approaches as well as establishing approaches through offshore capabilities.

Throughout her career in the industry, Sheryl has provided support to the successful filing and approval of over 100 life-changing medicines.

Currently, Sheryl is an advisor and consultant for biopharmaceutical companies.

Camilla Richmond, MD is a Medical Director of Translational Research in the Gastroenterology Drug Discovery Unit at Takeda. In this role, she oversees clinical development for early stage assets in the GI Cell Therapy and Neurogastroenterology/Motility portfolios. Dr Richmond has interest and experience in the design and implementation of decentralized clinical trial solutions and integration of novel digital tools as a mechanism to increase patient access to and diversity within clinical trials. Prior to joining Takeda, she was a physician-scientist at Boston Children’s Hospital and Assistant Professor at Harvard University Medical School. Dr Richmond continues to be a practicing pediatric gastroenterologist with a clinical focus in obesity medicine at Boston Children’s Hospital.

Daniel Millar leads Strategic Business Transformation in Statistics & Decision Sciences at J&J Innovative Medicine R&D and is an advocate for utilizing quantitative innovation to advance patient-centric R&D while simultaneously delivering transformational efficiencies. Mr Millar is a founding leader and champion for multi-stakeholder engagement in the Innovative Medicines Initiative (IMI) public-private partnership for Integrated Research Platforms, “EU PEARL.” Mr Millar was also a co-lead of the Clinical Trials Transformation Initiative (CTTI) project on Master Protocols together with leaders from FDA, academic research hospitals and patient advocacy. Daniel has served on and led DIA program committees for multi-stakeholder workshops focused on Complex Innovative Designs and Master Protocols. An important aspect of his focus has been generating a global discussion and knowledge exchange on innovative methods in clinical trial designs, including regulators in US, Brazil, Canada, Europe, UK, China and Japan, and bringing focus to the benefits of innovative designs for patients.

Mr Millar obtained an MBA from the University of Chicago Booth School of Business and a BA in Mathematics from the University of Pennsylvania. He lives in Manhattan and enjoys traveling.

Timothy Joy is the Head, Clinical Operations Strategic Solutions at Pfizer. Mr Joy is responsible for leading a global team tasked to identify and develop creative, scalable, technical and process related solutions for unmet global clinical trial needs.

Mr Joy has been at Pfizer since 2001, when he joined Development Informatics. In Development Informatics he was responsible for implementation and support of Pfizer Electronic Data Capture systems. Since joining Global Product Development in 2006 Mr Joy has held multiple positions with increasing responsibility. He represented Pfizer on an Industry council to redesign and implement enhanced versions of Electronic Data Capture, implement clinical and operational data warehouse, and most recently developing Pfizer’s Decentralized Clinical Trial strategy.

Mr Joy has been involved in numerous innovative projects and initiatives to redesign Investigator Site Support, implementation and usage of novel Patient Technologies, and creation of Pfizer’s eSource strategy.

Aman Thukral is the head of Digital Operations and Clinical Systems at AbbVie. He has over sixteen years of experience in clinical development, technology planning & business-technology alignment. Mr Thukral is responsible for Clinical Data Repository, eCOA operations, wearables, and sensors and for piloting new technology initiatives. Before this position, he worked at various levels at Deloitte, Cognizant & GlaxoSmithKline.

Brandon Maggio is a Director of Digital, Analytics & Performance, within Global Clinical Operations at GSK. Mr Maggio holds degrees in Biotechnology and Biochemical Pharmacology from the University at Buffalo and has dedicated 20 years to the pharmaceutical industry. He leads a diverse group of global innovators responsible for developing Digital Health strategies, implementing technology and innovative trial designs, optimizing processes to standardize new ways of working, and utilizing data to improve performance.

Daniela Graham (Dani), MD, is a trained pediatrician who has been doing clinical research/development in the inflammation and immunization space for over 12 years. Dr Graham has broad experience in regulatory submissions and advisory committees enabling successful interactions and effective communication with regulators. Dr Graham is currently working as a Global Clinical Lead in the Inflammation and Immunology therapeutic area for Pfizer.

Dr Graham was raised by two practicing physicians and knew from an early age that she wanted to pursue a career in medicine. Her desire to improve patient outcomes and positively impact multiple lives is a driving passion for her and gives her purpose. Working for Pfizer fuels her passion and purpose and as a leader in the organization,Dr Graham she is able to influence and inspire people internally.

Dr Graham is a mom of two children and loves spending time with them. Additionally, Dr Graham enjoys hiking with her dogs, the beach and developing delicious creations in her kitchen.